8-K: Annexon Initiates Phase 3 Trial for Geographic Atrophy Treatment, ANX007, Following Positive Phase 2 Results

Annexon has begun patient dosing in its Phase 3 ARCHER II trial for ANX007, a potential treatment for geographic atrophy, while also reporting positive data from its Phase 2 ARCHER trial.

Summary

• Annexon has commenced patient dosing in the global Phase 3 ARCHER II trial for ANX007, a treatment for geographic atrophy (GA).
• The ARCHER II trial is designed to evaluate ANX007's ability to protect vision, using best corrected visual acuity (BCVA) as the primary endpoint.
• The company also presented new data from the Phase 2 ARCHER trial at the American Society of Retina Specialists Annual Scientific Meeting.
• The Phase 2 data showed that ANX007 provided significant protection of vision and retinal structure, including photoreceptors, which are critical for visual acuity.
• The Phase 3 ARCHER II trial is expected to enroll approximately 630 patients and topline data is anticipated in the second half of 2026.
• ANX007 has received Priority Medicine (PRIME) designation in the European Union and Fast Track designation from the FDA.

Sentiment

Score: 8

Explanation: The document is very positive due to the initiation of the Phase 3 trial and the strong Phase 2 data showing significant vision protection. The company is also using a novel primary endpoint for the Phase 3 trial. However, the long timeline to topline data and the inherent risks of clinical trials temper the overall sentiment.

Positives

• The initiation of the Phase 3 ARCHER II trial is a significant step forward for ANX007.
• The Phase 2 ARCHER trial results demonstrate ANX007's potential to protect vision and retinal structure in GA patients.
• ANX007 is the only investigational medicine for GA to show significant protection of both visual acuity and key visual structures in a randomized clinical trial.
• The use of BCVA protection as the primary endpoint in ARCHER II is a novel approach for GA trials.
• ANX007 has received PRIME designation in the EU and Fast Track designation from the FDA, which may expedite its development and approval.
• The drug was generally well-tolerated in the Phase 2 trial with no increase in choroidal neovascularization (CNV) rates and no events of retinal vasculitis reported.

Negatives

• The Phase 3 trial is still ongoing, and there is no guarantee of success.
• Topline data from the Phase 3 trial is not expected until the second half of 2026, which is a long time away.
• The company is still in the clinical stage and has a history of net operating losses.

Risks

• The ARCHER II trial may not be successful, and ANX007 may not receive regulatory approval.
• There are risks associated with clinical trials, including potential side effects and the possibility of not meeting endpoints.
• The company may need to raise additional capital to fund its clinical programs.
• The company relies on third-party suppliers and manufacturers, which could pose risks to the supply chain.
• There are risks related to maintaining intellectual property rights for the product candidates.

Future Outlook

The company anticipates topline data from the Phase 3 ARCHER II trial in the second half of 2026 and is also planning an injection-controlled study, ARROW, to assess the prevention of 15-letter loss of BCVA.

Management Comments

• Douglas Love, president and chief executive officer of Annexon, stated that ANX007 is the only investigational medicine for GA to show significant protection of both visual acuity and key visual structures in a randomized clinical trial.
• Eleonora Lad, MD, PhD, Vice Chair of Clinical Research at Duke Eye Center, noted that the Phase 2 ARCHER trial data demonstrated protection of photoreceptors in the central fovea, which is critical for vision.

Industry Context

The announcement is significant as it highlights a potential new treatment for geographic atrophy, a leading cause of blindness in the elderly, where current treatments primarily focus on slowing disease progression rather than protecting vision. ANX007's focus on visual protection could be a major advancement in the field.

Comparison to Industry Standards

• Current FDA-approved treatments for GA primarily focus on slowing lesion growth by measuring protection of the retinal pigment epithelium (RPE).
• These treatments have not demonstrated significant protection of clinically meaningful vision for patients.
• ANX007 is unique in that it has shown protection of photoreceptors in the central fovea, which is critical for visual acuity.
• The use of best corrected visual acuity (BCVA) as the primary endpoint in the ARCHER II trial is a novel approach, as previous trials have focused on RPE loss.
• Companies like Apellis Pharmaceuticals and Iveric Bio have received FDA approval for GA treatments, but these treatments do not focus on vision protection as a primary endpoint.

Stakeholder Impact

• Shareholders may see a positive impact due to the progress of the clinical trial and positive data.
• Patients with geographic atrophy may benefit from a potential new treatment that protects vision.
• Employees of Annexon may be positively impacted by the company's progress.

Next Steps

• The company will continue to enroll patients in the Phase 3 ARCHER II trial.
• The company will continue to analyze data from the Phase 2 ARCHER trial.
• The company will continue to develop the ARROW study.

Key Dates

Keywords

Geographic Atrophy, ANX007, Phase 3 Trial, Vision Protection, Clinical Trial, Retinal Structure, Neurodegenerative Disease, Ophthalmology, BCVA, Photoreceptors